Amarin | AMRN - Bienes





Bienes Cambio Fecha
AbbVie USD 136.46B 2.5B 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amarin USD 645.76M 25.01M 2026-03
AstraZeneca USD 114.02B 59M 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
DBV Technologies USD 233.72M 123.22M 2025-12
Esperion Therapeutics USD 462.53M 3.36M 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Heron Therapeutics USD 246.22M 9.66M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novartis USD 118.53B 7.58B 2026-03